~~<i id='C8052956EC'><strike id='C8052956EC'><tt id='C8052956EC'><pre id='C8052956EC'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：comprehensive 2025-10-02 03:11:17 Page View：714

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Pfizer is about to make a big push in cancer. Will investors listen?
Next article： Walensky prepares to leave CDC — and Congress — behind

leisure time

How one medical school became remarkably diverse

ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

CDC advisory group OKs chikungunya vaccine

RickBowmer/APInaglobalfirst,sometravelersandlaboratoryresearcherswhoareatriskofcontractingchikunguny

Alkermes shareholders re

MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

David Ricks of Eli Lilly: best biopharma CEO of 2023

HyacinthEmpinado/STATIt’sthattimeoftheyearagainwhenIrecognizetheBestBiopharmaCEOoftheyear.Thisyear’s